EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-world drug survival of guselkumab in patients with psoriasis stratified by weight and comorbidities: retrospective, observational data from the British Association of Dermatologists Biologics and Immunomodulators Register

Laura J Savage, Maria-Angeliki Gkini, Xiayi Wang, Louise Topping, Bhavika Chauhan

Clinical and Experimental Dermatology · 2026-09-08

DOI: 10.1093/ced/llag363 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background In the UK, 89.1% of patients with moderate-to-severe psoriasis are overweight or obese, and 53.2% have at least one comorbidity. However, real-world data on biologic-treated patients with psoriasis and comorbidities remain limited. Objectives To compare 36-month drug survival of guselkumab in patients across weight and body mass index (BMI) categories, and in those with or without specific comorbidities. Methods This retrospective cohort study used data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), collected from January 2018 to July 2024. Co-primary outcomes were overall drug survival, and drug survival stratified by weight and BMI categories, over 36 months, for guselkumab-treated patients. Secondary outcomes included 36-month drug survival among guselkumab-treated patients with and without specific comorbidities, including but not limited to metabolic syndrome, hypertension, anxiety and/or depression. Kaplan–Meier methodology was used to estimate probabilities for time-to-treatment discontinuation across all patient groups analysed. Results Among the 482 participants included in this analysis who initiated guselkumab treatment, 36-month drug survival was generally high, with an overall drug survival rate of 0.75 [95% confidence interval (CI) 0.71–0.79]. Stratified by weight, drug survival rates were 0.71 (95% CI 0.59–0.86) for patients < 80 kg, 0.79 (95% CI 0.71–0.87) for those 80 to < 90 kg, 0.74 (95% CI 0.68–0.82) for those 90 to < 100 kg and 0.74 (95% CI 0.66–0.82) for those ≥ 100 kg. Drug survival by BMI category was 0.78 (95% CI 0.71–0.86) for patients < 30 kg m–2 and 0.73 (95% CI 0.69–0.79) for those ≥ 30 kg m–2. Across all comorbidities analysed, the drug survival rate at 36 months remained ≥ 0.69, with no significant differences observed in patients with comorbidities compared with those without. Conclusions In this UK real-world analysis, drug survival rates for guselkumab over 36 months were consistent across patients with psoriasis in different weight and BMI categories, and were not adversely affected by the presence of comorbidities. This analysis has limitations due to the high proportion of missing weight and BMI data at baseline. Nonetheless, these findings support guselkumab use as a durable treatment option in routine practice for patients with obesity and other common comorbidities.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →